B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1

B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 — Trials · CancerIndex

Clinical trials

Registered studies

39 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 18
Recruiting: 8
Ph III recruiting: 0
Growth YoY: —
Industry share: 6%
Top sponsor: M.D. Anderson Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04872790	Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia	active not recruiting	Phase 1	20	OHSU Knight Cancer InstituteOTHER	1	May 6, 2026	clinicaltrials

Data updated 22 days agoSource updated May 6, 2026source: clinicaltrials